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Abstract
We identified an amino acid change (p.G92E) in the Bone Morphogenetic Protein antagonist NOGGIN in a 22-month-old boy
who presented with a unilateral brachydactyly type B phenotype. Brachydactyly type B is a skeletal malformation that has
been associated with increased Bone Morphogenetic Protein pathway activation in other patients. Previously, the amino
acid change p.G92E in NOGGIN was described as causing fibrodysplasia ossificans progressiva, a rare genetic disorder
characterized by limb malformations and progressive heterotopic bone formation in soft tissues that, like Brachydactyly
type B, is caused by increased activation of Bone Morphogenetic Protein signaling. To determine whether G92E-NOGGIN
shows impaired antagonism that could lead to increased Bone Morphogenetic Protein signaling, we performed functional
assays to evaluate inhibition of BMP signaling. Interestingly, wt-NOGGIN shows different inhibition efficacies towards
various Bone Morphogenetic Proteins that are known to be essential in limb development. However, comparing the
biological activity of G92E-NOGGIN with wt-NOGGIN, we observed that G92E-NOGGIN inhibits activation of bone
morphogenetic protein signaling with equal efficiency as wt-NOGGIN, supporting that G92E-NOGGIN does not cause
pathological effects. Genetic testing of the child’s parents revealed the same amino acid change in the healthy father,
further supporting that p.G92E is a neutral amino acid substitution in NOGGIN. We conclude that p.G92E represents a rare
polymorphism of the NOGGIN gene - causing neither brachydactyly nor fibrodysplasia ossificans progressiva. This study
highlights that a given genetic variation should not be considered pathogenic unless supported by functional analyses.
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Introduction
NOGGIN (NOG) is a secreted homodimeric protein. The name
originates from the observation that high doses of NOG injected
into Xenopus laevis embryos caused excessive head development [1].
Later it was shown that NOG specifically inhibits activity of Bone
Morphogenetic Proteins (BMPs) and Growth and Differentiation
Factors (GDFs) with different efficacies [2–5]. BMPs were initially
identified as potent bone inducers by Marshall Urist [6]. Today it
is known that BMP function is not restricted to skeletal
development and regeneration, but fulfill essential functions in
several non-skeletal organs including brain, heart, liver, lung,
kidney and skin [7]. BMPs belong to the TGFb superfamily and
bind extracellularly to a heterotetrameric complex of type I and
type II receptors. The signal is transmitted into the nucleus via
phosphorylation of signaling molecules like SMADs, where gene
transcription is activated. A main mechanism controlling the
signaling cascade both spatially and temporarily are extracellular
antagonists like NOG. Analysis of the crystal structure of the
BMP7/NOG complex indicated that NOG inhibits signal
transmission by occluding the receptor binding site [8].
Imbalance between agonists, antagonists and receptors can
result in BMP linked disorders. As NOG is especially important in
bone development and function, NOG mutations are linked to
several skeletal diseases that are characterized either by joint
fusions and/or malformations of the phalanges [9]. Specifically,
NOG mutations are described to cause proximal symphalangism
(SYM1; OMIM #185800), multiple synostosis syndrome (SYNS,
OMIM: #186500), tarsal-carpal coalition syndrome (TCC;
OMIM #186570), stapes ankylosis with broad thumbs and toes
(OMIM #184460), and brachydactyly type B2 (BDB2; OMIM
#611377) as recently reviewed by Potti et al. [10]. All of these
phenotypes are the result of a misregulated BMP signaling
pathway during human skeletal development. BMP signaling is
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#135100), a rare and disabling autosomal dominant disorder
characterized by limb malformations and progressive heterotopic
bone formation that leads to complete ankylosis of nearly all joints
of the axial and appendicular skeleton [11–14]. In 2006, Shore
and colleagues linked FOP to chromosome 2q23-q24 and
identified the underlying genetic cause of FOP: a heterozygous
point mutation in the activin A type I receptor gene (ACVR1), a
BMP type I receptor, in all classically affected individuals
worldwide [15]. It was later shown that the identified missense
mutation in ACVR1 at position c.G617A leading to the amino acid
change p.R206H is an activating mutation [16].
Previous to the identification of ACVR1 mutations in FOP,
defects in the BMP signaling pathway had been hypothesized to be
responsible for FOP as BMPs regulate multiple steps in
development and can induce heterotopic osteogenesis [17,18].
Initially, BMP4 was considered a primary candidate as a disease-
causing gene as it is over-expressed in lesions of FOP patients, in
lymphoblastoid cells and in highly vascular pre-osseous fibropro-
liferative cells [19–21]. However, linkage analysis excluded
chromosome 14, the location of BMP4, and no mutations in
BMP4 could be found in FOP patients [15,22,23]. NOG, a potent
extracellular BMP antagonist, was also considered a candidate
gene for FOP [24,25] since BMP4 is antagonized by NOG and
also up-regulates NOG expression in a negative feedback loop
[2,26].
De novo mutations in the NOG gene in FOP patients were
reported, including the same guanine to adenine substitution at
nucleotide 275 leading to the amino acid change p.G92E that we
identified in our patient [27,28]. In response to such reports of the
involvement of NOG mutations in FOP [29–31], several studies
providing evidence that FOP is not linked to NOG mutations have
also been reported [32–37], establishing an unresolved issue
regarding whether NOG mutations can cause FOP.
NOG activity assays have been successfully established to
investigate the functional activity of NOG mutations in BDB2
patients [38] and are used in this study to evaluate the p.G92E
substitution. Here we provide evidence based on clinical as well as
experimental data that the amino acid change G92E in NOG does
not impair NOG function but represents a polymorphism of NOG.
Results
Patient
The patient of European descent was referred to the
department of clinical genetics at the age of 22 months. He
presented with unilateral atypical brachydactyly type B-like (BDB-
like) of the right hand and a negative family history (Fig. 1).
Clinically, his right hand showed shortening of the 3
rd to 5
th digits
with a rudimentary finger nail of 4
th digit. Missing middle and
distal phalanges and a hypoplastic proximal phalanx of the 4
th
finger as well as hypoplastic middle and distal phalanges of digits
III and V were demonstrated by a hand radiograph (Fig. 1A).
Both clinically and radiologically, the left hand did not show any
abnormality. His toes were normal and he had no heterotopic
ossification or any other skeletal features of FOP such as fused and
malformed cervical vertebrae, osteochondromas of the proximal
medial tibias, or short, broad femoral necks [39].
The patient was tested for mutations in two candidate genes for
BDB, ROR2 and NOG. Sequencing revealed no mutation in the
ROR2 gene, but a heterozygous substitution c.G275A, p.G92E in
the NOG gene. Analysis of the healthy parents showed that the
unaffected father also carried this substitution. Patient follow-up at
the age of 4 years revealed that apart from the unilateral
brachydactyly the boy was healthy and did not subsequently show
any signs of FOP.
Structural analysis of p.G92E
The single residue substitution in p.G92E is located within an
apparently highly flexible segment of the human NOG protein
called the polyglycine loop that comprises amino acid residues 89–
95 [8]. Due to the apparent lack of uniform structure and thus lack
of electron density in the computed maps to guide the process, the
polyglycine loop could not be modeled and incorporated into the
crystal structure (1M4U) deposited in the PDB (Fig. 2). NOG is a
dimeric extra-cellular protein that binds to and sequesters the
dimeric signal ligands, blocking recruitment of cell surface
receptors into a heteromeric signaling complex and transduction
of the signal across the membrane. Because the polyglycine loop
projects out into the solvent away from the ligand-binding
interface located on the opposite surface, direct interactions
between the substituted loop and BMP signal ligand are
precluded.
In vitro analysis of G92E-NOG
We investigated the G92E-NOG amino acid change in the in
vitro chicken micromass system to test whether this amino acid
change might alter NOG function and potentially cause
brachydactyly or FOP. Using a previously established assay for
BMP-induced chondrogenesis in micromass cultures [5], we
compared the ability of wt-NOG and G92E-NOG to block the
natural chondrogenesis of the cultures (Fig. 3A). Compared to the
uninfected control, both wt-NOG and G92E-NOG inhibited
chondrogenesis even when using very low virus titers. To assure
that the comparable activity of wt-NOG and G92E-NOG was not
due to differences in protein expression levels in the micromass
cells, we confirmed via western blot that the amount of wt-NOG
and G92E-NOG protein was similar in the cells. The uninfected
control contained no detectable NOG protein (Fig. 3B).
We further investigated the ability of wt-NOG and G92E-NOG
to inhibit the activity of a set of BMPs which are co-expressed
during limb development [40]. G92E-NOG was able to block all
tested BMPs in a comparable, dose dependent manner to wt-
NOG (Fig. 4). Comparison of the levels of inhibition of the BMPs
by NOG showed that Bmp7 had the highest sensitivity. With a
NOG titer of only 1/10 of the BMP titer, Bmp7-induced
chondrogenesis is nearly completely blocked whereas all other
BMPs remain able to induce chondrogenesis at this level of
competition. Both BMP2 and Bmp4 were antagonized efficiently
by both, wt-NOG and G92E-NOG, though less potently than
Bmp7. Of this tested set of BMPs, GDF5 was blocked least
efficiently by NOG but was still able to induce Alcian blue positive
nodules when NOG and GDF5 titers were equal.
Discussion
The clinical relevance of NOG missense mutations in FOP, a
rare but fatal genetic disorder, has been a matter of intense
discussion for nearly a decade [32–37]. Here we provide evidence
based on functional data that the G92E substitution in the NOG
protein does not cause FOP but rather represents a rare neutral
genetic polymorphism.
We identified G92E-NOG in a 22-month-old patient with an
atypical unilateral brachydactyly phenotype and in his healthy
father. Brachydactylies represent a group of skeletal disorders
characterized in general by shortened digits in hand and feet due
to abnormalities in the developmental process of phalanges or
metacarpals/metatarsals [41]. Brachydactyly type B1 (BDB1;
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whereas BDB2 is the result of mutations in NOG. As the patient
described here presented with unilateral atypical BDB-like
phenotype, sequencing of ROR2 and NOG was performed,
revealing the nucleotide substitution c.G275A in the NOG gene
resulting in the amino acid change p.G92E. A search through the
Human Gene Mutation Database indicated that G92E-NOG is
currently not associated with any type of brachydactyly but with
FOP.
In 2000, Lucotte and colleagues reported a genetic linkage
between NOG and FOP, whereas Xu et al. excluded such a linkage
between NOG and FOP and could not identify mutations of the
NOG gene in a large cohort of FOP patients [35,42]. In addition,
three novel mutations in NOG published by Semonin et al. were
subsequently challenged to be technical PCR errors due to the use
of a nested PCR approach [28,36]. Consequently, the necessity to
present photographs and radiographs of the studied FOP patients
has been emphasized to assure the correct clinical diagnosis and
that the same phenotypes are compared [34]. Upon identification
of heterozygous missense activating mutations in ACRV1 as the
genetic cause of FOP in 2006, additional questions regarding the
validity of NOG mutations in FOP were raised [15,27,30,33,37].
The nucleotide substitution c.G275A in the NOG gene leading
to p.G92E was described for two patients with FOP of Spanish
origin. Of note, one of the patients was also positive for the
p.R206H mutation in ACVR1, raising the question of the
likelihood that two ‘‘pathogenic’’ mutations causing a genetic
disorder as rare as FOP would be found in a single patient [27,28].
Our patient with unilateral atypical BDB-like phenotype and his
healthy farther were positive for the amino acid change c.G275A,
p.G92E in the NOG gene previously described to be a cause of
FOP [27,28]. Neither of these two individuals, the now 4-year-old
boy or his 42-year-old father, showed any clinical features of FOP
whatsoever.
From a structural standpoint, the substitution in p.G92E is
situated in the most flexible portion of the NOG protein, a
segment not interpretable from the electron density maps of the
3D-structure determination [8] (Fig. 2). Unlike much of the
Figure 1. Patient phenotype. X-rays of the patients hands (A) were taken before the operation, at the age of 4 months, showing the unilateral
atypical BDB-like phenotype. Photographs of hands (B) and feet (C) were taken after the surgical correction, at the age of 22 months. Note that the
middle phalanx of the 3rd left toe was removed and implanted as the middle phalanx of the 3rd finger of the right hand in order to stabilize the digit
and improve functionality. The pedigree (D) shows the patient carrying the heterozygous change p.G92E in NOG which he inherited from the healthy
father.
doi:10.1371/journal.pone.0035062.g001
Figure 2. Three-dimensional model of the NOG-BMP7 complex highlighting the unstructured polyglycine loop that harbors the
substitution in p.G92E. NOG-BMP7 complex (PDB: 1M4U) is depicted as a cartoon structure, with monomers of the NOG homodimer in dark in
light green and monomers of the BMP7 homodimer in red and orange with surfaces depicted (A). Labeled residues flank the polyglycine loop, which
is unresolved due to an apparent high flexibility associated with the largely unrestricted chain of residues. The NOG monomers on the left are tilted
slightly into, and the BMP monomers slightly out of, the image plane. The complex in the zoomed view (B) is tilted further in the same direction, as
well as slightly counter-clockwise about the perpendicular axis.
doi:10.1371/journal.pone.0035062.g002
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and complex formation, the polyglycine segment is not conserved
among different species. For example, in dogs the loop is expanded
yet in non-mammals is completely absent [43]. Moreover, the
residue at position 92 is distal to and oriented away from the
ligand-binding interface, consistent with the neutral effect of the
substitution on function as an antagonist.
Further, using experimental assays for BMP signaling, we did
not identify differences between wild-type and mutant NOG
protein to inhibit control chicken micromass cells (Fig. 3). This
observation is in contrast to disease causing NOG mutations like
P35R or R167G, where chicken micromass controls are shown to
be less efficiently blocked compared to the wt-NOG [38].
However, in the same publication of Lehmann et al. some BDB
causing NOG mutations did also not show a loss of inhibitory
activity on chicken micromass control cells, like A36P and P187S.
Hence we expanded our approach to compare the ability of
G92E-NOG and wt-NOG to block chondrogenesis in chicken
micromass cells expressing BMPs/GDFs known to be essential in
limb development. We showed that BMP2, Bmp4, Bmp7 and
GDF5 are blocked by wt-NOG and G92E-NOG comparably in a
dose dependent manner (Fig. 4). As the tested BMPs are all
known to be crucial players during limb patterning, changes in
NOG affinity for these BMPs could have provided an explanation
for the hand phenotype of the patient [5,40]. It should be noted,
that in contrast to previous data, Bmp7 was antagonized very
efficiently by NOG when compared to BMP2, Bmp4 and GDF5
[2]. Furthermore, NOG had been hypothesized to cause FOP
through decreased antagonism of BMP4 since this BMP was found
to be over-expressed in lesions of FOP patients [20]. However, if a
mutation in NOG resulted in FOP due to decreased BMP4
antagonism, this would have been readily apparent in the chicken
micromass system (Fig. 4). As there is no difference in Bmp4
antagonism comparing wt-NOG and G92E-NOG, we can exclude
this path of pathogenicity. The general applicability of chicken
micromass cultures for the evaluation of FOP causing mutations
has been demonstrated as mutations in ACVR1 do result in
changes in BMP signaling which can be monitored in this system
[16].
The absence of differences between G92E-NOG and wt-NOG
in our functional tests supports that the observed unilateral
atypical BDB-like phenotype in our patient is not due to the
polymorphism in NOG. His malformation is more likely caused by
an isolated local disruption of embryonic vessels during early
development. Polygenic or multifactorial developmental distur-
bances rather than single gene germline mutations are thought to
be the cause of many unilateral limb defects, especially with
respect to hereditary monogenic types of brachydactylies as these
generally manifest bilaterally [44]. Furthermore, empirical data
support our interpretation. In the exome sequence variant
database of the Seattle University (http://evs.gs.washington.edu/
EVS) 25 of 10129 alleles (23 of European American origin; 2 of
African American origin) are listed containing the G92E exchange
[45]. This implies a population allele frequency of 1/400. As both
FOP and BDB are rare genetic disorders, it is very unlikely that
G92E-NOG causes either of these diseases. We conclude that the
G92E change in NOG is a polymorphism neither causing BDB
nor FOP.
Our analysis raises important issues with respect to genetic
counseling. Since the G92E amino acid change in NOG is
reported to be pathogenic for FOP in many databases, such as the
Human Gene Mutation Database, parents could be wrongly
informed that their child has a FOP causing mutation when, in
fact, a neutral polymorphism has been identified. In our opinion it
is imperative that this fact becomes common knowledge and noted
in the relevant database, and further that other NOG mutations
described to cause FOP are evaluated through experimental tests.
The necessity of such functional assays for the evaluation of
putatively disease causing mutations was recently underlined by
several studies. For example, genome information of Dr. James
Watson by next-generation sequencing technology identified 20
mutations associated with increased disease risks without becom-
ing manifest in the apparently healthy carrier [46,47]. This notion
was also supported in a larger scale by MacArthur et al. who
Figure 3. Biological activity of wt-NOG and G92E-NOG and protein production in chicken micromass cells are comparable. Chicken
micromass cells were infected with either wt-NOG or G92E-NOG from 1*10e07 viral particles/ml and decreasing to 0.05*10e07 viral particles/ml (A). At
day 5, cells were stained with Alcian blue, and dye concentration quantified spectrophotometrically at 595 nm. Non-infected controls were
normalized as 100% activity. Data shown are taken from a representative experiment performed with 3 replicates each. Error bars indicate standard
deviation. Pellets from cells infected with 1*10e07 viral particles/ml were collected at day 3 from the same chicken micromass experiment to perform
Western Blot analysis (B). Uninfected cells were used as a control. After SDS-PAGE under non-reducing conditions and subsequent Western Blot, NOG
and b-Actin were detected with specific antibodies. For quantification, NOG was normalized to b-Actin. Wt-NOG and G92E-NOG are expressed in
equal amounts in the micromass cultures.
doi:10.1371/journal.pone.0035062.g003
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complete loss-of-function mutations in protein-coding genes
without phenotypic consequences, suggesting an unexpected high
degree of redundancy in the human genome [48]. It is predicted
that for the majority of human genes a single functional allele is
sufficient to exert the normal function [49]. Considering these
results, functional assays are indispensable to analyze the potential
pathogenicity of a mutation.
Materials and Methods
Ethics statement
Clinical investigations have been conducted according to the
principles expressed in the Declaration of Helsinki. Ethical
approval of the study was given by the ethical board Charite ´.
Written informed consent for genetic testing was received from all
analyzed individuals or by parents on behalf of their child.
Molecular Analysis of patient and parents
Genomic DNA was extracted from peripheral blood samples by
standard methods. The coding regions of tyrosine kinase-like
orphan receptor 2 gene (ROR2) and NOG as well as the flanking
intronic sequences were amplified by standard PCR protocols.
The primer sequences and PCR conditions for the molecular
testing were previously published (for NOG: [38]; for ROR2: [50]).
PCR products were analyzed on 2% agarose gels. Sequencing was
done using the ABI Prism BigDye Terminator Sequencing Kit
(Applied Biosystems, Foster City, CA, USA) with PCR primers
used as sequencing primers. Products were evaluated on an
automated capillary sequencer (Applied Biosystems 3730, Foster
City, CA, USA). Identified sequence changes were evaluated using
dbSNP135 and the Human Gene Mutation Database (HGMD)
(https://portal.biobase-international.com/hgmd) as a reference.
NOG-BMP7 complex
The image of the three-dimensional structure of NOG-BMP7
complex was produced from the PDB-file 1M4U [8] rendered by
PyMOL Molecular Graphics System, Version 1.2r3pre, Schro ¨-
dinger, LLC.
Virus preparation
Mouse Bmp4 in RCAS-A was provided by Pip Francis-West
[51], human GDF5 in RCAS-A was previously described [52].
Coding sequences of human BMP2, mouse Bmp7 and human NOG
Figure 4. wt-NOG and G92E-NOG show comparable ability to block BMP targets in the chicken Micromass system. Chicken micromass
cells were infected with 1*10e07 viral particles/ml containing the gene for BMP2 (A), Bmp4 (B), Bmp7 (C) or GDF5 (D). Co-infection was performed
with increasing virus titers of either wt-NOG or G92E-NOG as indicated. At day 5, cells were stained with Alcian blue, and dye concentration quantified
spectrophotometrically at 595 nm. Controls infected exclusively with BMPs were normalized as 100% activity. Data shown are taken from a
representative experiment performed with 3 replicates each. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0035062.g004
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13. In vitro mutagenesis for human NOG was performed with the
QuickChange Site-Directed Mutagenesis Kit (Agilent Biotechnol-
ogies, Santa Clara, CA, USA) BMP2, GDF5 and Bmp7 were
cloned into RCAS(BP)A. Wild-type (wt)-NOG and G92E-NOG
were cloned into RCAS(BP)B to allow co-expression of NOG with
different BMPs. Cloning into retroviral vectors, production of viral
supernatant in DF1 cells and concentration of viral particles was
performed as described previously [53]. In short, DF1 cells were
transfected with RCAS retroviral vectors and supernatant
harvested at 3 consecutive days. Viral particles were concentrated
via ultra-centrifugation, followed by determination of viral titer
through infection of DF-1 cells (ATCC: UMNSAH/DF-1 #CRL-
12203) and counting of cells positive for an RCAS specific
antibody.
Chicken Micromass Culture System
Chicken micromass cultures were primary isolated from limb
buds of day 4.5 chicken embryos and performed as previously
described [38]. Cells were plated at a density of 2610e05 cells/
14 ml-drop. Single and co-infections were performed with
concentrated viral supernatants adjusted to 1610e07 infectious
units/ml. To evaluate chondrogenesis, micromass cultures were
fixed and stained with 0.05% Alcian blue. Alcian blue staining was
quantified after extraction with 6 M guanidine-HCl and spectro-
photometically measured at 595 nm.
Western Blotting
Western Blot analysis was performed as previously described
[38] with minor changes: Micromass cells were harvested at day 3
and lysed in lysis buffer (50 mM HEPES, 50 mM NaCl, 10 mM
EDTA, 10% glycerol, 1% Triton, 100 mM PMSF). Immunode-
tection was performed using an anti-NOG antibody (sc-25656,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), and an anti-
Actin antibody (A5441, Sigma-Aldrich, St.Louis, MO, USA) as
primary antibodies. Signals were detected via IRDye labeled
secondary antibodies (IRDye goat anti rabbit 800; IRDye goat
anti mouse 680, LICOR, Lincoln, NE, USA) and quantified using
the Odyssey infrared imaging system (LICOR).
Acknowledgments
We thank Maria Walther for technical support and Lutz Schomburg for
critical remarks on the manuscript.
Author Contributions
Conceived and designed the experiments: JZ SCD DH JCG EMS FSK PS.
Performed the experiments: JZ SCD. Analyzed the data: JZ SCD DH JCG
EMS FSK PS. Contributed reagents/materials/analysis tools: JZ SCD
JCG PS. Wrote the paper: JZ SCD PS.
References
1. Smith WC, Harland RM (1992) EXPRESSION CLONING OF NOGGIN, A
NEW DORSALIZING FACTOR LOCALIZED TO THE SPEMANN
ORGANIZER IN XENOPUS EMBRYOS. Cell 70: 829–840.
2. Zimmerman LB, DeJesusEscobar JM, Harland RM (1996) The Spemann
organizer signal noggin binds and inactivates bone morphogenetic protein 4.
Cell 86: 599–606.
3. Beck HN, Drahushuk K, Jacoby DB, Higgins D, Lein PJ (2001) Bone
morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured
sympathetic neurons. Bmc Neuroscience 2.
4. Song K, Krause C, Shi S, Patterson M, Suto R, et al. (2010) Identification of a
Key Residue Mediating Bone Morphogenetic Protein (BMP)-6 Resistance to
Noggin Inhibition Allows for Engineered BMPs with Superior Agonist Activity.
Journal of Biological Chemistry 285: 12169–12180.
5. Seemann P, Brehm A, Koenig J, Reissner C, Stricker S, et al. (2009) Mutations
in GDF5 Reveal a Key Residue Mediating BMP Inhibition by NOGGIN. Plos
Genetics 5.
6. Urist MR (1965) BONE - FORMATION BY AUTOINDUCTION. Science
150: 893-&.
7. Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic protein
receptors and signal transduction. Journal of Biochemistry 147: 35–51.
8. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, et al.
(2002) Structural basis of BMP signalling inhibition by the cystine knot protein
Noggin. Nature 420: 636–642.
9. Seemann P, Mundlos S, Lehmann K (2008) Alterations of BMP signaling
pathway(s) in skeletal diseases Bone Morphogenetic Proteins: From Local to
Systemic Therapeutics. In: Vukicevic S, Sampath KT, eds. Birkha ¨user Basel. pp
141–159.
10. Potti TA, Petty EM, Lesperance MM (2011) A Comprehensive Review of
Reported Heritable Noggin-Associated Syndromes and Proposed Clinical Utility
of One Broadly Inclusive Diagnostic Term: NOG-Related-Symphalangism
Spectrum Disorder (NOG-SSD). Human Mutation 32: 877–886.
11. Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, et al. (1993) THE
NATURAL-HISTORY OF HETEROTOPIC OSSIFICATION IN PA-
TIENTS WHO HAVE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
- A STUDY OF 44 PATIENTS. Journal of Bone and Joint Surgery-American
Volume 75A: 215–219.
12. Connor JM, Evans DAP (1982) FIBRODYSPLASIA OSSIFICANS PRO-
GRESSIVA - THE CLINICAL-FEATURES AND NATURAL-HISTORY
OF 34 PATIENTS. Journal of Bone and Joint Surgery-British Volume 64:
76–83.
13. Connor JM, Skirton H, Lunt PW (1993) A 3 GENERATION FAMILY WITH
FIBRODYSPLASIA OSSIFICANS PROGRESSIVA. Journal of Medical
Genetics 30: 687–689.
14. Kaplan FS, Tabas JA, Gannon FH, Finkel G, Hahn GV, et al. (1993) THE
HISTOPATHOLOGY OF FIBRODYSPLASIA OSSIFICANS PROGRES-
SIVA - AN ENDOCHONDRAL PROCESS. Journal of Bone and Joint
Surgery-American Volume 75A: 220–230.
15. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, et al. (2006) A
recurrent mutation in the BMP type I receptor ACVR1 causes inherited and
sporadic fibrodysplasia ossificans progressiva. Nat Genet 38: 525–527.
16. Shen Q, Little SC, Xu M, Haupt J, Ast C, et al. (2009) The fibrodysplasia
ossificans progressiva R206H ACVR1 mutation activates BMP-independent
chondrogenesis and zebrafish embryo ventralization. Journal of Clinical
Investigation 119: 3462–3472.
17. Kaplan FS, Tabas JA, Zasloff MA (1990) FIBRODYSPLASIA OSSIFICANS
PROGRESSIVA - A CLUE FROM THE FLY. Calcified Tissue International
47: 117–125.
18. Rosen V, Thies RS (1992) THE BMP PROTEINS IN BONE-FORMATION
AND REPAIR. Trends in Genetics 8: 97–102.
19. Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, et al. (1996)
Overexpression of an osteogenic morphogen in fibrodysplasia ossificans
progressiva. New England Journal of Medicine 335: 555–561.
20. Gannon FH, Kaplan FS, Olmsted E, Finkel GC, Zasloff MA, et al. (1997) Bone
morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia
ossificans progressiva. Human Pathology 28: 339–343.
21. Lanchoney TF, Olmsted EA, Shore EM, Gannon FA, Rosen V, et al. (1998)
Characterization of bone morphogenetic protein 4 receptor in fibrodysplasia
ossificans progressiva. Clinical Orthopaedics and Related Research. pp 38–45.
22. Tabas JA, Hahn GV, Cohen RB, Seaunez HN, Modi WS, et al. (1993)
CHROMOSOMAL ASSIGNMENT OF THE HUMAN GENE FOR BONE
MORPHOGENETIC PROTEIN-4. Clinical Orthopaedics and Related
Research. pp 310–316.
23. Xu MQ, Shore EM (1998) Mutational screening of the bone morphogenetic
protein 4 gene in a family with fibrodysplasia ossificans progressiva. Clinical
Orthopaedics and Related Research. pp 53–58.
24. Brunet LJ, McMahon JA, McMahon AP, Harland RM (1998) Noggin, cartilage
morphogenesis, and joint formation in the mammalian skeleton. Science 280:
1455–1457.
25. Gong YQ, Krakow D, Marcelino J, Wilkin D, Chitayat D, et al. (1999)
Heterozygous mutations in the gene encoding noggin affect human joint
morphogenesis. Nature Genetics 21: 302–304.
26. Gazzerro E, Gangji V, Canalis E (1998) Bone morphogenetic proteins induce
the expression of noggin, which limits their activity in cultured rat osteoblasts.
Journal of Clinical Investigation 102: 2106–2114.
27. Lucotte G, Houzet A, Hubans C, Lagarde JP, Lenoir G (2009) MUTATIONS
OF THE NOGGIN (NOG) AND OF THE ACTIVIN A TYPE I RECEPTOR
(ACVR1) GENES IN A SERIES OF TWENTY-SEVEN FRENCH FIBRO-
DYSPLASIA OSSIFICANS PROGRESSIVA (FOP) PATIENTS. Genetic
Counseling 20: 53–62.
Pathogenic Relevance of Alleged NOG Mutation G92E
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e3506228. Semonin O, Fontaine K, Daviaud C, Ayuso C, Lucotte G (2001) Identification
of three novel mutations of the noggin gene in patients with fibrodysplasia
ossificans progressiva. American Journal of Medical Genetics 102: 314–317.
29. Fontaine K, Semonin O, Lagarde JP, Lenoir G, Lucotte G (2005) A new
mutation of the Noggin gene in a French Fibrodysplasia ossificans progressiva
(FOP) family. Genetic Counseling 16: 149–154.
30. Lucotte G, Lagarde JP, European Research G (2007) Mutations of the noggin
and of the activin a type I receptor genes in fibrodysplasia ossificans progressiva
(FOP). Genetic Counseling 18: 349–352.
31. Lucotte G, Semonin O, Lutz P (1999) A de novo heterozygous deletion of 42
base-pairs in the noggin gene of a fibrodysplasia ossificans progressiva patient.
Clinical Genetics 56: 469–470.
32. Cohen MM (2002) Bone morphogenetic proteins with some comments on
fibrodysplasia ossificans progressiva and NOGGIN. American Journal of
Medical Genetics 109: 87–92.
33. Kaplan FS, Xu M, Feldman G, Brown M, Cho TJ, et al. (2008) RESPONSE
TO ‘‘MUTATIONS OF THE NOGGIN AND OF THE ACTIVIN A TYPE I
RECEPTOR GENES IN FIBRODYSPLASIA OSSIFICANS PROGRES-
SIVA (FOP)’’ by Lucotte et al. Genetic Counseling 19: 357–359.
34. Warman ML (2002) Significant difference of opinion regarding the role of
noggin in fibrodysplasia ossificans progressiva. American Journal of Medical
Genetics 109: 162–162.
35. Xu MQ, Feldman G, Le Merrer M, Shugart YY, Glaser DL, et al. (2000)
Linkage exclusion and mutational analysis of the noggin gene in patients with
fibrodysplasia ossificans progressiva (FOP). Clinical Genetics 58: 291–298.
36. Xu MQ, Shore EM, Kaplan FS (2002) Reported noggin mutations are PCR
errors. American Journal of Medical Genetics 109: 161–161.
37. Seemann P, Mundlos S (2008) THE TALE OF FOP, NOGGIN AND
MYRISTOYLATION: NO DATA, NO PROOF! Genetic Counseling 19:
353–355.
38. Lehmann K, Seemann P, Silan F, Goecke TO, Irgang S, et al. (2007) A new
subtype of brachydactyly type B caused by point mutations in the bone
morphogenetic protein antagonist NOGGIN. American Journal of Human
Genetics 81: 388–396.
39. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, et al. (2009) Classic and
atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by
mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
Human Mutation 30: 379–390.
40. Albrecht AN, Schwabe GC, Stricker S, Boddrich A, Wanker EE, et al. (2002)
The synpolydactyly homolog (spdh) mutation in the mouse - a defect in
patterning and growth of limb cartilage elements. Mechanisms of Development
112: 53–67.
41. Bell J (1951) On brachydactyly and symphalangism University Press.
42. Lucotte G, Bathelier C, Mercier G, Lenoir G, Semonin O, et al. (2000)
Localisation of the gene for fibrodysplasia ossificans progressiva (FOP) to
chromosome 17q21-22 and noggin gene as candidate for FOP. Developmental
Dynamics 219: 459–459.
43. Ishii Y, Takizawa T, Iwasaki H, Fujita Y, Murakami M, et al. (2011) Nucleotide
Polymorphisms in the Canine Noggin Gene and Their Distribution Among Dog
(Canis lupus familiaris) Breeds. Biochem Genet.
44. Schwabe GC, Mundlos S (2004) Genetics of congenital hand anomalies.
Handchir Mikrochir Plast Chir 36: 85–97.
45. NHLBI Exome Sequencing Project (ESP) S, WA (05.03.2012) Exome Variant
Server.
46. Wadman M (2008) James Watson’s genome sequenced at high speed. Nature
452: 788–788.
47. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, et al. (2008) The
complete genome of an individual by massively parallel DNA sequencing.
Nature 452: 872–U875.
48. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, et al.
(2012) A systematic survey of loss-of-function variants in human protein-coding
genes. Science 335: 823–828.
49. Huang N, Lee I, Marcotte EM, Hurles ME (2010) Characterising and Predicting
Haploinsufficiency in the Human Genome. Plos Genetics 6.
50. Schwabe GC, Tinschert S, Buschow C, Meinecke P, Wolff G, et al. (2000)
Distinct mutations in the receptor tyrosine kinase gene ROR2 cause
brachydactyly type B. American Journal of Human Genetics 67: 822–831.
51. Duprez D, Bella EJD, Richardson MK, Archer CW, Wolpert L, et al. (1996)
Overexpression of BMP-2 and BMP-4 alters the size and shape of developing
skeletal elements in the chick limb. Mechanisms of Development 57: 145–157.
52. Ploeger F, Seemann P, Kegler MS-v, Lehmann K, Seidel J, et al. (2008)
Brachydactyly type A2 associated with a defect in proGDF5 processing. Human
Molecular Genetics 17: 1222–1233.
53. Morgan BA, Fekete DM (1996) Manipulating gene expression with replication-
competent retroviruses. Methods in Cell Biology, Vol 51 51: 185–218.
Pathogenic Relevance of Alleged NOG Mutation G92E
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35062